How to Buy Day One Biopharmaceuticals Stock
Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers.
Day One Biopharmaceuticals stock last closed at $6.67, down 0.3% from the previous day, and has decreased 48.37% in one year. It has overperformed other stocks in the Biotechnology industry by 0.28 percentage points. Day One Biopharmaceuticals stock is currently +9.7% from its 52-week low of $6.08, and -60.2% from its 52-week high of $16.76.
At the moment, there are 101.36M DAWN shares outstanding. The market cap of DAWN is $676.09M. In the past 24 hours, 1.16M DAWN shares were traded.
How to Buy Day One Biopharmaceuticals Stock
Wondering how to invest in Day One Biopharmaceuticals stock? Here's how.
- Decide where to buy Day One Biopharmaceuticals stock: You need to choose a stock brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you determine where to buy Day One Biopharmaceuticals stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit money your investment account: Choose your payment method and add your details.
- Analyze Day One Biopharmaceuticals stock: The Day One Biopharmaceuticals ticker symbol is DAWN. Is Day One Biopharmaceuticals stock a good investment? Should you buy shares of DAWN? How do DAWN's underlying business fundamentals look? Do top analysts think Day One Biopharmaceuticals is a good buy? Why has DAWN's stock price moved recently? (Hint: Our stock research tools can help you understand if DAWN is a good stock to buy).
- Place your DAWN trade: Decide if you will purchase DAWN shares at the current market price or use a limit order to buy DAWN stock at a particular price.
- Monitor your investment in DAWN: Create a watchlist to keep track of your position in Day One Biopharmaceuticals stock.
Step 1: Decide where to buy Day One Biopharmaceuticals stock
You will need a brokerage account to access the NASDAQ market and buy DAWN shares.
Our favorite brokerage: eToro
In our opinion, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to global markets: From Technology to Utilities, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've picked the right brokerage, it's time to fill out some personal info so you are able to invest in DAWN stock today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to start your new trading account.
- Send your details by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you have filled out your info on the best stock trading app, you need to deposit funds:
Watch the video below if you need help depositing money into your brokerage account.
Step 4: Analyze Day One Biopharmaceuticals stock
Once you have decided on the best place to buy Day One Biopharmaceuticals stock, it's crucial to research their stock prior to investing, so you can wrap your head around the risk and opportunity.
Day One Biopharmaceuticals Numbers
DAWN Due Diligence Checks
WallStreetZen was created to help average investors do more accurate fundamental analysis.
You can see all of the due diligence checks on DAWN's stock page.
What is the fair value of DAWN stock?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge DAWN's fair value.
Using relative valuations methods:
- DAWN may be undervalued based on its P/B ratio of 1.41x, relative to Biotechnology industry P/B ratio of 4.66x
You can do more valuation research on DAWN's stock here.
DAWN Financial Summary
Positive Financial Indicators:
- There are more short-term assets than long-term liabilities on the DAWN balance sheet.
- DAWN has a low debt to equity ratio of 0.11.
- There are more short-term assets than short-term liabilities on the DAWN balance sheet.
Negative Financial Indicators:
- DAWN profit margin has gone down from N/A to -42.7% in the past year.
- DAWN's operating cash flow of -$87.38M allows it to safely service it's debt of $2.92M.
- DAWN earnings of -$61.94M is not sufficient to cover its interest payments.
Is it a good time to buy DAWN stock, according to analysts?
Out of 6 Wall Street analysts who research DAWN, the consensus analyst rating on DAWN is a Strong Buy
Please note that analyst ratings are not recommendations, nor are they investment advice.
Latest DAWN Analyst Recommendations
Alec Stranahan, a bottom 3% analyst from Bank of America maintains DAWN with a strong buy rating and lowers their DAWN price target from $28.00 to $25.00, on Jan 7, 2025.
An analyst from Jones Trading maintains DAWN with a strong buy rating and lowers their DAWN price target from $39.00 to $34.00, on Dec 17, 2024.
You can dive deeper into what analysts are forecasting on the Day One Biopharmaceuticals stock forecast page.
DAWN Momentum
What are DAWN executives and large shareholders up to?
Over the past 12 months, insiders at DAWN have sold more shares than they have bought.
Jeremy Bender, CHIEF EXECUTIVE OFFICER of DAWN, was the latest DAWN insider to sell. They sold $87,386.71 worth of DAWN stock on May 16, 2025.
Research more about who owns DAWN shares here.
Can I get consistent income from DAWN stock?
No, Day One Biopharmaceuticals doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Place your DAWN trade
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are generally fine for most investors. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at an exact price, place a limit order.
Click the Open button and eToro will place the order.
If you want additional assistance buying stocks on eToro, click the helpful video below:
Step 6: Monitor your investment in DAWN
Now that you own some DAWN shares, you'll want to stay up-to-date on your investment.
Make a watchlist to get notified of the latest news about your DAWN stock.
DAWN Feed
How to Buy Stock in Day One Biopharmaceuticals
To reiterate, here are the 6 steps to buy Day One Biopharmaceuticals stock:
- Decide where to buy Day One Biopharmaceuticals stock
- Open your brokerage account
- Deposit money your investment account
- Analyze Day One Biopharmaceuticals stock
- Place your DAWN trade
- Monitor your investment in DAWN
If you are looking for a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you want to monitor your investment in Day One Biopharmaceuticals, create a watchlist today.
Other "How To" Guides You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.